# Belite Bio Inc American (BLTE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $193.61, market value $7.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Belite Bio Inc American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 10.0×**. The shares trade at 10.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -0.5%** (5-yr avg -1.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -10.1%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -95.8%**. Earnings per share fell 95.8%.

## Financial health
- **Current ratio: 50.02** (quick 50.02). Current assets cover the next year's liabilities 50.02 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Belite Bio Inc American does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 197.2%** (YTD 21.0%, 3-mo 35.1%). The shares are up 197.2% over twelve months including dividends.
- **From 52-week high: -3.2%** (198.8% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 73**. An RSI of 73 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.90** (volatility 55%). Beta of 0.90 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BLTE · Page: https://foliofundamentals.com/stocks/blte

Not investment advice.